efficacy and safety of a novel pegylated interferon alpha-2a in egyptian patients with genotype 4 chronic hepatitis c
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

efficacy and safety of a novel pegylated interferon alpha-2a in egyptian patients with genotype 4 chronic hepatitis c

;Alaa Awad Taha;Ahmad El-Ray;Maged El-Ghannam;Bahaa Mounir
indian journal of pharmacology 2010 Vol. 24 pp. 597-602
187
taha2010canadianefficacy

Abstract

BACKGROUND: Hepatitis C virus (HCV) genotype 4 is a common infection in Egypt and is the leading cause of liver disease.

Keywords

Gastroenterology diseases of the digestive system

Access

DOI:
10.1155/2010/717845
URL:
http://dx.doi.org/10.1155/2010/717845

Citation

ID: 251427
Ref Key: taha2010canadianefficacy
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
251427
Unique Identifier:
10.1155/2010/717845
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store